Preetam Shah bought CDTX once, on Nov 12, 2021

Preetam Shah, Ph.D., MBA is a seasoned healthcare finance executive and corporate insider with more than 20 years of experience in biotechnology, consulting, and investment banking.( He most recently served as Chief Financial Officer and Chief Business Officer (CFO, CBO) and later Chief Financial Officer and Principal Accounting Officer at Cidara Therapeutics, Inc. (NASDAQ: CDTX), a clinical-stage biotechnology company developing long-acting compounds, including its Cloudbreak® drug-Fc-conjugate platform for influenza and oncology.( In these roles, he oversaw finance, business development, capital markets activities, and strategic partnering, and was a reporting corporate insider in Cidara’s SEC filings.(

Dr. Shah currently serves as Chief Strategy and Financial Officer at Elicio Therapeutics, Inc. (Nasdaq: ELTX), where he leads corporate strategy and financial operations for the company’s immunotherapy pipeline based on its lymph node–targeting Amphiphile (AMP) platform.( His prior career includes senior healthcare investment banking roles at Barclays Capital, Lordes Capital, and Canaccord Genuity, as well as executive leadership positions such as Chief Financial Officer, Treasurer, and Executive Vice President at Brainstorm Cell Therapeutics.( He is also the founder of Saisarva LLC, established in 2010.( Dr. Shah holds a Ph.D. in microbiology (doctorate from the University of Mississippi Medical Center) and an MBA from The Wharton School of the University of Pennsylvania, combining scientific training with advanced finance and management expertise.(

Written by Perplexity from public sources.